CCP stands for Covid-19 Convalescent Plasma, plasma collected from former patients who have recovered from Covid-19. CCP contains antibodies that could neutralize SARS-CoV-2 and thus may improve disease course in patients with Covid-19 .
SUPPORT-E Project: Covid-19 caused by the newly identified severe acute respiratory syndrome virus 2 (SARS-CoV-2) is spreading worldwide and has provoked a global health crisis.
To date, no specific antiviral treatment has been proven efficient and no vaccine is available yet. Therapeutic options for Covid-19 mainly focus on supportive care, e.g. oxygenation, mechanical ventilation and fluid management, and treatment of secondary infections. Hence there is a need for new curative strategies
that preferably have already been used in clinical practice and are widely available and scalable. Based on clinical experiences from previous epidemics, the use of convalescent plasma from recovered Covid-19 patients may provide a therapeutic solution.
However, successful adoption of this strategy in clinical practice in Europe still requires extensive clinical testing and would therefore benefit from a coordinated approach between Blood Establishments (BEs), clinical centres and competent authorities across Europe to support and accelerate high-quality evaluation of CCP.
In this context, the formulation of evidence-based recommendations based on scientific and clinical insights coming from newly developed standardized assays and evaluation of CCP donor and recipient data will be of paramount importance.
Support High Quality
Support High Quality CCP Evaluation in clinical trials and monitored access use programmes
Deliver Recommendations for the collection and use of CCP in EU member states to treat Covid-19
Deliver Recommendations for future outbreaks
Ensure EU wide adoptions of recommendations and project legacy